Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 28, 2023 02:00 ET | Source: Cancer Advances Inc

Cancer Advances, Inc. Announces Issuance of New U.S. Patent

DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal (GI) cancers, announced that the U.S....
March 09, 2022 09:30 ET | Source: Roots Analysis

The opportunity within the regulatory T-cell therapies market is projected to grow at an annualized rate of ~45%, till 2035, claims Roots Analysis

London, March 09, 2022 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Regulatory T-Cell (Tregs) Therapies Market, 2021 – 2035” report to its list of offerings. Given the various...
August 24, 2021 10:30 ET | Source: Cancer Advances Inc

Cancer Advances, Inc. Announces Publication, “Vaccination with Polyclonal Antibody Stimulator (PAS) Prevents Pancreatic Carcinogenesis in the KRAS Mouse Model" in Cancer Prevention Research

DURHAM, N.C., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, announces a new publication in...
May 19, 2021 08:00 ET | Source: TeneoBio, Inc

Teneobio’s Clinical Candidate, TNB-409, is a Selective IL-2 Receptor Bispecific Agonist for the Treatment of Solid Tumors

NEWARK, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage biotech company focused on the discovery and development of novel multi-specific biotherapeutic antibodies,...
January 21, 2020 22:20 ET | Source: Cancer Advances Inc

Cancer Advances, Inc. Announces Poster Presentation at ASCO GI

DURHAM, N.C., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, will present a poster at the...
February 25, 2019 05:00 ET | Source: QANTU Therapeutics, Inc.

Key Patent Issued on Qantu's QT-0101 Adjuvant

LEWISVILLE, Texas, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Qantu Therapeutics, Inc. announces the issuance of United States patent 10,195,257 titled “Vaccine Formulations Comprising Quillaja...